Poseida Net Income From Continuing Ops from 2010 to 2025
| PSTX Stock | USD 9.50 0.08 0.84% |
Net Loss | First Reported 2019-06-30 | Previous Quarter -31.4 M | Current Value 20.2 M | Quarterly Volatility 26.6 M |
Check Poseida Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Poseida Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 10.5 M, Income Tax Expense of 101.1 K or Tax Provision of 129.2 K, as well as many indicators such as Price To Sales Ratio of 5.12, Dividend Yield of 0.0 or PTB Ratio of 4.84. Poseida financial statements analysis is a perfect complement when working with Poseida Therapeutics Valuation or Volatility modules.
Poseida | Net Income From Continuing Ops |
Latest Poseida Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Poseida Therapeutics over the last few years. It is Poseida Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Poseida Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Poseida Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (59,883,522) | |
| Geometric Mean | 43,113,026 | |
| Coefficient Of Variation | (78.22) | |
| Mean Deviation | 42,156,462 | |
| Median | (19,662,000) | |
| Standard Deviation | 46,841,300 | |
| Sample Variance | 2194.1T | |
| Range | 110.1M | |
| R-Value | (0.85) | |
| Mean Square Error | 646.3T | |
| R-Squared | 0.73 | |
| Significance | 0.000029 | |
| Slope | (8,377,661) | |
| Total Sum of Squares | 32911.6T |
Poseida Net Income From Continuing Ops History
About Poseida Therapeutics Financial Statements
Poseida Therapeutics investors use historical fundamental indicators, such as Poseida Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Poseida Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -111.1 M | -116.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for Poseida Stock Analysis
When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.